Week 2: estrogens and progesterones Flashcards
1
Q
Estrogen -route of administration
A
- Oral
- goes through first pass metabolism and first pass hepatic effect
- high conc. of estrogens in liver induces synthesis of proteins with adverse (TE, HTN, gallstone) and beneficial effects (lipoproteins) - Non oral: transdermal, vaginal, intramuscular route
- diluted in systemic circulation
- bound to protein
2
Q
Transport of estrogens in body
A
- Estradiol has high affinity to sex hormone binding globulin (SHBG) and low affinity for albumin
- estrogen conjugates and ethinyl estradiol have high affinity for albumin
- free estrogen is physiologically active
3
Q
Metabolism of estrogens
A
- hydroxylated by microsomal enzymes in liver to derivatives that are glucuronidated or sulfated
- inactive products excreted in urine
- conjugated metabolites also subjected to enterohepatic recirculation: excreted in bile, converted to free estrogens by intestinal bacteria, reabsorbed into circulation
4
Q
Natural estrogens
A
- Estradiol: not used orally because of first pass hepatic metabolism
-miconized (small particle) prep: can be used orally, but in high doses because of low bioavailability - Transdermal estradiol: releases over 1 week
Uses: ERT for post menopausal women. Rarely used.
5
Q
Conjugated esters
A
- Conjugated equine estrogen (Premarin)
- contains at least 10 components, mostly estrone and equilin
- most common used estrogen for ERT - Estrone esters (synthetic)
- easily hydrolyzed in gut and absorbed. Low first pass metabolism.
6
Q
Ethinyl estradiol
A
- synthetic steroid estrogen, with ethanol group at C17. Reduces metabolism
- half life is ~2- hrs
- useful as contraceptive
- not regulated by SHBG. While induces SHBG (like natural estradiol), EE doesn’t bind to SHBG. EE can regulated SHBG, E2, and androgen levels.
- natural estrogen self regulates since it induces SHBG, and binds to it
7
Q
side effects of estrogen
A
- minor: few for ERT. As OCP, breast tenderness, edema, nausea
- Major
- Endometrial cancer: unopposed estrogen. The addition of progestogen reduces risk.
- breast cancer
- HTN: Angiotensinogen synthesis stimulated. majority of women will reduce renin. However, some won’t due to genetics, and have HTN.
- Thromboembolism: increased synthesis of clotting factors in liver. Minimized with transdermal delivery
- Gallstone formation: estrogen increases cholesterol excretion in bile
- CV disease: controversial
8
Q
Contraindications of estrogen therapy
A
- pregnancy: high doses teratogenic but not low doses (as in OCPs)
- breast and endometrial cancers
- hepatic disease
- undiagnosed genital bleeding
- thromboembolic diseases
9
Q
ERT applications for post menopausal conditions
A
- vasomotor symptoms
- premarin widely used
- if have breast cancer taking tamoxifen, treat with clonidine, gabapentine, SNRI - Genitourinary atrophy
- vaginally administered estrogen cream - osteoporosis
- hysterectemized women: ERT
- intact uterus: low dose ERT, or HRT
10
Q
Raloxifene
A
- SERM: selective estrogen receptor modulator
- undergoes extensive glucuronidation
- used for osteoporosis and breast cancer prevention
- adverse: DVT, PE, hot flashes, cramps
- agonist in: bone
- antagonist: breast, uterus, vasomotor symptoms
11
Q
Clomiphene
A
- related to tamoxifen.
- acts as anti estrogen and estrogen (SERM)
- oral
- used to treat anovulatory infertility and infertility related to PCOD. Antagonists estrogen receptors in hypothalamus and pit (blocks negative feedback), increases GnRH and FSH/LH- thereby inducing follicular dev. and ovulation
- adverse: multiple births
12
Q
Progestogens
A
- C21 -derivative of progesterone
- medroxyprogesterone acetate: long half life. oral or IM. Used for HRT, Depo-provera. - C19: derivative of testosterone.
- estranes: norethinedrone
- gonanes: levonorgestrel, norgestimate